SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-052954
Filing Date
2023-04-28
Accepted
2023-04-28 16:10:58
Documents
13
Period of Report
2023-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm232020-2_def14a.htm DEF 14A 914267
2 GRAPHIC bc_netloss-4c.jpg GRAPHIC 151505
3 GRAPHIC bc_paidtsr-4c.jpg GRAPHIC 159129
4 GRAPHIC ic_internet-bw.jpg GRAPHIC 7342
5 GRAPHIC ic_mail-bw.jpg GRAPHIC 3933
6 GRAPHIC ic_tele-bw.jpg GRAPHIC 3822
7 GRAPHIC lg_sellaslifesciences-4clr.jpg GRAPHIC 34841
8 GRAPHIC px_annualmeetingbroker01-4c.jpg GRAPHIC 651380
9 GRAPHIC px_annualmeetingbroker02-4c.jpg GRAPHIC 676741
10 GRAPHIC px_annualmeetingcommon01-4c.jpg GRAPHIC 1080110
11 GRAPHIC px_annualmeetingcommon02-4c.jpg GRAPHIC 820893
12 GRAPHIC sg_angelosmstergiou-bw.jpg GRAPHIC 17405
13 GRAPHIC sg_barbaraawood-bw.jpg GRAPHIC 19447
  Complete submission text file 0001104659-23-052954.txt   5398439
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33958 | Film No.: 23866190
SIC: 2834 Pharmaceutical Preparations